Discovery of AC710, a globally selective inhibitor of platelet-derived growth factor receptor-family kinases

ACS Medicinal Chemistry Letters

Volumn 3, Issue 12, 2012, Pages 997-1002

  Liu, Gang ^a   Campbell, Brian T ^a,c   Holladay, Mark W ^a   Ford Pulido, Julia M ^a,d   Hua, Helen ^a   Gitnick, Dana ^b,e   Gardner, Michael F ^b   James, Joyce ^b,f   Breider, Mike A ^b,g   Brigham, Daniel ^a,h   Belli, Barbara ^a   Armstrong, Robert C ^a   Treiber, Daniel K ^a,i  

^a Department of Medicinal Chemistry ^*  (United States)

^b DMPK   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Astute Medical   (United States)

^e DART NEUROSCIENCE LLC   (United States)

^f Cytokinetics Inc   (United States)

^g CELGENE CORPORATION   (United States)

^h Aragon Pharmaceuticals Inc   (United States)

ⁱ DiscoveRx Corporation   (United States)

Author keywords

AC710; acute myeloid leukemia (AML); cancer bone metastasis; colony stimulating factor 1 receptor (CSF1R) inhibitor; feline McDonough sarcoma (FMS) like tyrosine kinase 3 (FLT3); inflammatory arthritis; platelet derived growth factor receptor (PDGFR) family kinases

Indexed keywords

AC 710; DEXAMETHASONE; NITROGEN; PHOSPHOTRANSFERASE INHIBITOR; PIPERIDINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; METHYLATION; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; REDUCTION; SOLUBILIZATION; TUMOR XENOGRAFT;

FELIDAE; RATTUS;

EID: 84871204335     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300214g     Document Type: Article

References (29)

1. Zwick, E.; Bange, J.; Ullrich, A. Receptor Tyrosine Kinase Signalling as a Target for Cancer Intervention Strategies Endocr. Relat. Cancer 2001, 8, 161-173
2. Schlessinger, J. Cell Signaling by Receptor Tyrosine Kinases Cell 2000, 103, 211-225
3. Roskoski, R., Jr. Sunitinib: A VEGF and PDGF Receptor Protein Kinase and Angiogenesis Inhibitor Biochem. Biophys. Res. Commun. 2007, 356, 323-328
4. Abu-Duhier, F. M.; Goodeve, A. C.; Care, R. S.; Gari, M.; Wilson, G. A.; Peake, I. R.; Reilly, J. T. Mutational Analysis of Class III Receptor Tyrosine Kinases (C-KIT, C-FMS, FLT3) in Idiopathic Myelofibrosis Br. J. Hemaetol. 2003, 120, 464-470
5. Gilliland, D. G.; Griffin, J. D. The Roles of FLT3 in Hematopoiesis and Leukemia Blood 2002, 100, 1532-1542
6. Zarrinkar, P. P.; Gunawardane, R. N.; Cramer, M. D.; Gardner, M. F.; Brigham, D.; Belli, B.; Karaman, M. W.; Pratz, K. W.; Pallares, G.; Chao, Q.; Sprankle, K. G.; Patel, H. K.; Levis, M.; Armstrong, R. C.; James, J.; Bhagwat, S. S. AC220 is a Uniquely Potent and Selective Inhibitor of FLT3 for the Treatment of Acute Myeloid Leukemia (AML) Blood 2009, 114, 2984-2992
7. Cortes, J.; Perl, A.; Smith, C.; Kovacsovics, T.; Dombret, H.; Dohner, H.; Steffen, B.; Pigneux, A.; Rousselot, P.; Krauter, J.; Martinelli, G.; Estey, E.; Burnett, A.; Ho, A.; Ifrah, N.; de Witte, T.; Corringham, R.; James, J.; Lilienfeld, D.; Leo, E.; Trikha, M.; Levis, M. A Phase II Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients with Acute Myeloid Leukemia (AML) with FLT3-ITD Activating Mutations: Interim Results. 16th Congress of the European Hematology Association (London, England, 2011).
8. Pixley, F. J.; Stanley, E. R. CSF-1 Regulation of the Wandering Macrophage: Complexity in Action Trends Cell Biol. 2004, 14, 628-638
9. Chitu, V.; Stanley, E. R. Colony-stimulating Factor-1 in Immunity and Inflammation Curr. Opin. Immunol. 2006, 18, 39-48
10. Douglass, T. G.; Driggers, L.; Zhang, J. G.; Hoa, N.; Delgado, C.; Williams, C. C.; Dan, Q.; Sanchez, R.; Jeffes, E. W. B.; Wepsic, H. T.; Myers, M. P.; Koths, K.; Jadus, M. R. Macrophage Colony Stimulating Factor: Not Just for Macrophages Anymore! A Gateway into Complex Biologies Int. Immunopharmacol. 2008, 8, 1354-1376
11. Teitelbaum, S. L. Osteoclasts: What Do They Do and How Do They Do it? Am. J. Pathol. 2007, 170, 427-435
12. Bingle, L.; Brown, N. J.; Lewis, C. E. The Role of Tumour-Associated Macrophages in Tumour Progression: Implications for New Anticancer Therapies J. Pathol. 2002, 196, 254-265
13. Priceman, S. J.; Sung, J. L.; Shaposhnik, Z.; Burton, J. B.; Torres-Collado, A. X.; Moughon, D. L.; Johnson, M.; Lusis, A. J.; Cohen, D. A.; Iruela-Arispe, M. L.; Wu, L. Targeting Distinct Tumor-Infiltrating Myeloid Cells by Inhibiting CSF-1 Receptor: Combating Tumor Evasion of Antiangiogenic Therapy Blood 2010, 115, 1461-1471
14. Manthey, C. L.; Johnson, D. L.; Illig, C. R.; Tuman, R. W.; Zhou, Z.; Baker, J. F.; Chaikin, M. A.; Donatelli, R. R.; Franks, C. F.; Zeng, L.; Crysler, C.; Chen, Y.; Yurkow, E. J.; Boczon, L.; Meegalla, S. K.; Wilson, K. J.; Wall, M. J.; Chen, J.; Ballentine, S. K.; Ott, H.; Baumann, C.; Lawrence, D.; Tomczuk, B. E.; Molloy, C. J. JNJ-28312141, a Novel Orally Active Colony-Stimulating Factor-1 Receptor/FMS-Related Receptor Tyrosine Kinase-3 Receptor Tyrosine Kinase Inhibitor with Potential Utility in Solid Tumors, Bone Metastases, and Acute Myeloid Leukemia Mol. Cancer Ther. 2009, 8, 3151-3161
15. Kitaura, H.; Zhou, P.; Kim, H.-J.; Novack, D. V.; Ross, F. P.; Teitelbaum, S. L. M-CSF Mediates TNF-Induced Inflammatory Osteolysis J. Clin. Invest. 2005, 115, 3418-3427
16. Weitzmann, M. N.; Cenci, S.; Rifas, L.; Brown, C.; Pacifici, R. IL-7 Stimulates Osteoclast Formation by Upregulating the T-Cell Production of Soluble Osteoclastogenic Cytokines Blood 2000, 96, 1873-1878
17. Campbell, I. K.; Rich, M. J.; Bischof, R. J.; Hamilton, J. A. The Colony-Stimulating Factors and Collagen-Induced Arthritis: Exacerbation of Disease by M-CSF and G-CSF and Requirement for Endogenous M-CSF J. Leukocyte Biol. 2000, 68, 144-150
18. Conway, J. G.; Pink, H.; Bergquist, M. L.; Han, B.; Depee, S.; Tadepalli, S.; Lin, P.; Crumrine, R. C.; Binz, J.; Clark, R. L.; Selph, J. L.; Stimpson, S. A.; Hutchins, J. T.; Chamberlain, S. D.; Brodie, T. A. Effects of the cFMS Kinase Inhibitor 5-(3-Methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4- diamine (GW2580) in Normal and Arthritic Rats J. Pharmacol. Exp. Ther. 2008, 326, 41-50
19. Illig, C. R.; Manthey, C. L.; Wall, M. J.; Meegalla, S. K.; Chen, J.; Wilson, K. J.; Ballentine, S. K.; DesJarlais, R. L.; Schubert, C.; Crysler, C. S.; Chen, Y.; Molloy, C. J.; Chaikin, M. A.; Donatelli, R. R.; Yurkow, E.; Zhou, Z.; Player, M. R.; Tomczuk, B. E. Optimization of a Potent Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors Leading to Anti-Inflammatory Clinical Candidate 4-Cyano-n-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)- Acetyl]-4-piperidinyl]phenyl]-1h-imidazole-2-carboxamide (JNJ-28312141) J. Med. Chem. 2011, 54, 7860-7883
20. http://www.plexxikon.com/view.cfm/97/Press-Releases.
21. Davis, M. I.; Hunt, J. P.; Herrgard., S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive Analysis of Kinase Inhibitor Selectivity Nat. Biotechnol. 2011, 29, 1046-1051 and references cited therein
22. Patel, H. K.; Grotzfeld, R. M.; Lai, A. G.; Mehta, S. A.; Milanov, Z. V.; Chao, Q.; Sprankle, K. G.; Carter, T. A.; Velasco, A. M.; Fabian, M. A.; James, J.; Treiber, D. T.; Lockhart, D. J.; Zarrinkar, P. P.; Bhagwat, S. S. Arylcarboxyamino-Substituted Diaryl Ureas as Potent and Selective FLT3 Inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 5182-5185
23. Milanov, Z. V.; Mehta, S. A.; Lai, A. G.; Grotzfeld, R. M.; Patel, H. K.; Lockhart, D. J. Urea Derivatives as Kinase Modulators. WO2005/48948 A2, 2005.
24. Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds Chem. Rev. 1995, 95, 2457-2483
25. Phapale, V. B.; Cárdenas, D. J. Nickel-Catalysed Negishi Cross-Coupling Reactions: Scope and Mechanisms Chem. Soc. Rev. 2009, 38, 1598-1607
26. Molander, G. A.; Sandrock, D. L. Aminomethylations via Cross-coupling of Potassium Organotrifluoroborates with Aryl Bromides Org. Lett. 2007, 9, 1597-1600
27. Wodicka, L. M.; Ciceri, P.; Davis, M. I.; Hunt, J. P.; Floyd, M.; Salerno, S.; Hua, X. H.; Ford, J. M.; Armstrong, R. A.; Zarrinkar, P. P.; Treiber, D. K. Activation State-Dependent Binding of Small Molecule Kinase Inhibitors: Structural Insights from Biochemistry Chem. Biol. 2010, 17, 1241-1249
28. Sun, H.; Scott, D. O. Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design ACS Med. Chem. Lett. 2011, 2, 638-643
29. Conway, J. G.; McDonald, B.; Parham, J.; Keith, B.; Rusnak, D. W.; Shaw, E.; Jansen, M.; Lin, P.; Payne, A.; Crosby, R. M.; Johnson, J. H.; Frick, L.; Lin, M. H.; Depee, S.; Tadepalli, S.; Votta, B.; James, I.; Fuller, K.; Chambers, T. J.; Kull, F. C.; Chamberlain, S. D.; Hutchins, J. T. Inhibition of Colony-Stimulating-Factor-1 Signaling in vivo with the Orally Bioavailable cFMS Kinase Inhibitor GW2580 Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 16078-16083